Akihiro Sugai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Akihiro Sugai has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Osamu Onodera
Department of Neurology, Brain Research Institute, Niigata University; Niigata, 951-8585, Japan
12 shared publications Shingo Koide
Department of Neurology, Brain Research Institute, Niigata University; Niigata, 951-8585, Japan
6 shared publicationsTakuma Yamagishi
Department of Neurology, Brain Research Institute, Niigata University; Niigata 951-8585, Japan
6 shared publicationsAya Washida
Department of Neurology, Brain Research Institute, Niigata University; Niigata, 951-8585, Japan
5 shared publications- Tomohiko Ishihara
Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan
5 shared publications - Yuka Koike
Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan
5 shared publications
Latest Publications
- Open Access
Exitron-type splicing of intrinsically disordered regions recurs across jawed vertebrates despite sequence divergence: donor-proximal cis control in TARDBP
Intrinsically disordered regions (IDRs) mediate molecular interactions but can also promote aberrant self-association. Using donors embedded within IDR-coding sequences, exitron-type splicing can remove these sequences, giving them both protein-coding and splice-regulatory roles. Yet IDR amino-acid sequences often diverge rapidly, raising the question of whether and how their coding sequences support IDR-removing splicing across species. Using RNA-seq data from jawed vertebrates, we identified events predicted to remove most of an IDR while preserving annotated structured regions. Across species, donor-flanking nucleotide identity exceeded expectations from synonymous alternatives encoding the same amino-acid sequence. TARDBP , which encodes TDP-43, provided a model for examining how coding sequences both encode IDRs and regulate exitron-type splicing. Sequence-divergent vertebrate TARDBP terminal regions supported this splicing in human cells. In teleosts, TARDBP ohnologs ( tardbpa and tardbpb ) encoded compositionally similar disordered tails but differed markedly in IDR-removing exitron-type splicing. Reciprocal donor-proximal substitutions in zebrafish minigenes redirected donor choice and altered the balance between IDR-retaining and IDR-removing transcripts. In corresponding reporters, these substitutions altered protein-product balance and cytoplasmic puncta formation. These findings show that IDR-removing exitron-type splicing can recur despite sequence divergence and that donor-proximal TARDBP sequences both encode IDR segments and regulate IDR inclusion, linking RNA processing to protein behavior.
Open AccessExitron-type splicing of intrinsically disordered regions recurs across jawed vertebrates despite sequence divergence: donor-proximal cis control in TARDBP
Intrinsically disordered regions (IDRs) mediate molecular interactions but can also promote aberrant self-association. Using donors embedded within IDR-coding sequences, exitron-type splicing can remove these sequences, giving them both protein-coding and splice-regulatory roles. Yet IDR amino-acid sequences often diverge rapidly, raising the question of whether and how their coding sequences support IDR-removing splicing across species. Using RNA-seq data from jawed vertebrates, we identified events predicted to remove most of an IDR while preserving annotated structured regions. Across species, donor-flanking nucleotide identity exceeded expectations from synonymous alternatives encoding the same amino-acid sequence. TARDBP , which encodes TDP-43, provided a model for examining how coding sequences both encode IDRs and regulate exitron-type splicing. Sequence-divergent vertebrate TARDBP terminal regions supported this splicing in human cells. In teleosts, TARDBP ohnologs ( tardbpa and tardbpb ) encoded compositionally similar disordered tails but differed markedly in IDR-removing exitron-type splicing. Reciprocal donor-proximal substitutions in zebrafish minigenes redirected donor choice and altered the balance between IDR-retaining and IDR-removing transcripts. In corresponding reporters, these substitutions altered protein-product balance and cytoplasmic puncta formation. These findings show that IDR-removing exitron-type splicing can recur despite sequence divergence and that donor-proximal TARDBP sequences both encode IDR segments and regulate IDR inclusion, linking RNA processing to protein behavior.
- Open Access
- 4 August 2026
- Published by Elsevier in Neurobiology of Disease
- Vol. 228, 107560
Persistent export bias of TDP-43 under native autoregulation links insoluble accumulation to nuclear dysfunction
- 4 August 2026
- Published by Elsevier in Neurobiology of Disease
- Vol. 228, 107560
Open AccessPersistent export bias of TDP-43 under native autoregulation links insoluble accumulation to nuclear dysfunction
- Open Access
Export‑biased, 3′UTR‑preserving TDP‑43 model links nuclear loss to cytoplasmic aggregation in ALS/FTLD
Nuclear depletion and cytoplasmic mislocalization of TDP-43 are central pathological features of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. TDP-43 protein levels are normally maintained by autoregulation through its native 3′ untranslated region (3′ UTR). It remains untested whether this feedback is still protective once the perturbation is chronic, and whether the resulting rise in TARDBP transcripts restores the functional nuclear pool or is instead diverted into non-functional species. To address this, we engineered full-length human TDP-43 carrying an N-terminal nuclear export signal (NES) while leaving the native 3′ UTR autoregulatory module intact. Expression was titrated so that whole-cell RIPA-soluble exogenous TDP-43 remained ≤30% of endogenous levels. In HEK293T cells, export bias drove TDP-43 into the cytoplasm and produced detergent-insoluble species. In differentiated SH-SY5Y cells, nuclear splicing defects and autoregulatory changes scaled with export-biased load, and detergent-insoluble accumulation was already present within the same low-load range. Human iPSC-derived neurons showed a comparable cytoplasmic shift, discrete TDP-43-positive foci, and TDP-43-dependent splicing defects. When endogenous TDP-43 was selectively depleted under transgene induction, 3′ UTR-coupled autorepression was weakened and transgene-derived TARDBP transcripts rose; however, the additional exogenous TDP-43 did not expand the soluble, splice-competent pool but partitioned into insoluble fractions. Splicing defects in differentiated SH-SY5Y cells persisted even when soluble NES–TDP-43 reached endogenous-equivalent levels. We therefore propose that under native 3′ UTR control, sustained cytoplasmic bias uncouples compensatory TARDBP upregulation from recovery of the functional nuclear pool; the extra output is diverted into insoluble, fragmented species rather than restoring nuclear function.
Open AccessExport‑biased, 3′UTR‑preserving TDP‑43 model links nuclear loss to cytoplasmic aggregation in ALS/FTLD
Nuclear depletion and cytoplasmic mislocalization of TDP-43 are central pathological features of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. TDP-43 protein levels are normally maintained by autoregulation through its native 3′ untranslated region (3′ UTR). It remains untested whether this feedback is still protective once the perturbation is chronic, and whether the resulting rise in TARDBP transcripts restores the functional nuclear pool or is instead diverted into non-functional species. To address this, we engineered full-length human TDP-43 carrying an N-terminal nuclear export signal (NES) while leaving the native 3′ UTR autoregulatory module intact. Expression was titrated so that whole-cell RIPA-soluble exogenous TDP-43 remained ≤30% of endogenous levels. In HEK293T cells, export bias drove TDP-43 into the cytoplasm and produced detergent-insoluble species. In differentiated SH-SY5Y cells, nuclear splicing defects and autoregulatory changes scaled with export-biased load, and detergent-insoluble accumulation was already present within the same low-load range. Human iPSC-derived neurons showed a comparable cytoplasmic shift, discrete TDP-43-positive foci, and TDP-43-dependent splicing defects. When endogenous TDP-43 was selectively depleted under transgene induction, 3′ UTR-coupled autorepression was weakened and transgene-derived TARDBP transcripts rose; however, the additional exogenous TDP-43 did not expand the soluble, splice-competent pool but partitioned into insoluble fractions. Splicing defects in differentiated SH-SY5Y cells persisted even when soluble NES–TDP-43 reached endogenous-equivalent levels. We therefore propose that under native 3′ UTR control, sustained cytoplasmic bias uncouples compensatory TARDBP upregulation from recovery of the functional nuclear pool; the extra output is diverted into insoluble, fragmented species rather than restoring nuclear function.
- 22 October 2025
- Published by Wiley in FEBS Letters
- Vol. 600 (1) , 119-130
Quantifying subpercent nuclear TDP ‐43 loss in cells and ALS cortex using junction‐specific cryptic exon RT ‐ qPCR
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are progressive neurodegenerative diseases characterised by nuclear TDP‐43 loss. Its hallmark, cryptic exon (CE) splicing, is often masked in bulk tissue analyses by the low abundance of affected neurons. We developed an ultrasensitive RT‐qPCR assay targeting STMN2 CE using one exon–CE junction‐spanning primer and the other within the CE. The design expands the dynamic range sevenfold: TDP‐43 knockdown boosted STMN2 CE levels 1395‐fold in differentiated SH‐SY5Y neurons. Spike‐in tests set detection at 0.16% deficient cells. Crucially, the assay revealed a 42‐fold CE increase in ALS motor cortex, previously missed by conventional primers. This streamlined tool enables precise quantification of TDP‐43 dysfunction and sensitive pharmacodynamic monitoring for future ALS‐FTD therapeutic studies. Impact statement: Because cryptic‐exon signals are diluted in bulk tissue, we developed a junction‐spanning STMN2 RT‐qPCR with sub‐percent sensitivity. This deployable biomarker will aid ALS/FTD researchers and drug developers by standardizing measurements and enabling sensitive pharmacodynamic monitoring of therapies targeting nuclear TDP‐43 dysfunction.
- 22 October 2025
- Published by Wiley in FEBS Letters
- Vol. 600 (1) , 119-130
Quantifying subpercent nuclear TDP ‐43 loss in cells and ALS cortex using junction‐specific cryptic exon RT ‐ qPCR
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are progressive neurodegenerative diseases characterised by nuclear TDP‐43 loss. Its hallmark, cryptic exon (CE) splicing, is often masked in bulk tissue analyses by the low abundance of affected neurons. We developed an ultrasensitive RT‐qPCR assay targeting STMN2 CE using one exon–CE junction‐spanning primer and the other within the CE. The design expands the dynamic range sevenfold: TDP‐43 knockdown boosted STMN2 CE levels 1395‐fold in differentiated SH‐SY5Y neurons. Spike‐in tests set detection at 0.16% deficient cells. Crucially, the assay revealed a 42‐fold CE increase in ALS motor cortex, previously missed by conventional primers. This streamlined tool enables precise quantification of TDP‐43 dysfunction and sensitive pharmacodynamic monitoring for future ALS‐FTD therapeutic studies. Impact statement: Because cryptic‐exon signals are diluted in bulk tissue, we developed a junction‐spanning STMN2 RT‐qPCR with sub‐percent sensitivity. This deployable biomarker will aid ALS/FTD researchers and drug developers by standardizing measurements and enabling sensitive pharmacodynamic monitoring of therapies targeting nuclear TDP‐43 dysfunction.
- Open Access
ASO-enhancement of TARDBP exitron splicing mitigates TDP-43 proteinopathies
Amyotrophic lateral sclerosis and frontotemporal lobar degeneration are fatal neurodegenerative diseases characterized by pathological aggregation and nuclear functional loss of TDP-43 1,2 . Current therapies inadequately address this core pathology 3,4 , necessitating innovative approaches that target aggregation while preserving TDP-43’s essential functions. Here we demonstrate that enhancing the splicing of the TARDBP exitron—a cryptic intron encoding the aggregation-prone intrinsically disordered region (IDR) of TDP-43 5,6 — effectively mitigates TDP-43 pathology. This exitron splicing event, directly regulated by nuclear TDP-43 7–9 , suppresses the expression of IDR-containing TDP-43 isoforms and generates IDR-spliced-out TDP-43 isoforms 7,9,10 (which we term “IDRsTDP”). Our findings reveal that IDRsTDP, known to heterodimerize with full-length TDP-43 10 , inhibits TDP-43 aggregation by suppressing IDR-mediated clustering and enhances TDP-43 clearance via chaperone-mediated autophagy. In disease states, however, impaired nuclear TDP-43 function disrupts exitron splicing, leading to increased levels of IDR-containing TDP-43 9,11 and reduced levels of IDRsTDP, exacerbating aggregation and nuclear dysfunction 6,12–17 . By identifying HNRNPA1 and HNRNPC as key repressors of TARDBP exitron splicing, we designed antisense oligonucleotides (ASOs) to block their binding and restore splicing. These ASOs suppressed TDP-43 pathology and neurodegeneration in both neuronal cell models with impaired nuclear transport and a mouse model of proteasome dysfunction-induced TDP-43 proteinopathy. Our strategy, by rescuing the impaired autoregulatory pathway, inhibits the pathological cycle of TDP-43 aggregation and nuclear dysfunction, offering a promising avenue for treating these currently intractable neurodegenerative diseases.
Open AccessASO-enhancement of TARDBP exitron splicing mitigates TDP-43 proteinopathies
Amyotrophic lateral sclerosis and frontotemporal lobar degeneration are fatal neurodegenerative diseases characterized by pathological aggregation and nuclear functional loss of TDP-43 1,2 . Current therapies inadequately address this core pathology 3,4 , necessitating innovative approaches that target aggregation while preserving TDP-43’s essential functions. Here we demonstrate that enhancing the splicing of the TARDBP exitron—a cryptic intron encoding the aggregation-prone intrinsically disordered region (IDR) of TDP-43 5,6 — effectively mitigates TDP-43 pathology. This exitron splicing event, directly regulated by nuclear TDP-43 7–9 , suppresses the expression of IDR-containing TDP-43 isoforms and generates IDR-spliced-out TDP-43 isoforms 7,9,10 (which we term “IDRsTDP”). Our findings reveal that IDRsTDP, known to heterodimerize with full-length TDP-43 10 , inhibits TDP-43 aggregation by suppressing IDR-mediated clustering and enhances TDP-43 clearance via chaperone-mediated autophagy. In disease states, however, impaired nuclear TDP-43 function disrupts exitron splicing, leading to increased levels of IDR-containing TDP-43 9,11 and reduced levels of IDRsTDP, exacerbating aggregation and nuclear dysfunction 6,12–17 . By identifying HNRNPA1 and HNRNPC as key repressors of TARDBP exitron splicing, we designed antisense oligonucleotides (ASOs) to block their binding and restore splicing. These ASOs suppressed TDP-43 pathology and neurodegeneration in both neuronal cell models with impaired nuclear transport and a mouse model of proteasome dysfunction-induced TDP-43 proteinopathy. Our strategy, by rescuing the impaired autoregulatory pathway, inhibits the pathological cycle of TDP-43 aggregation and nuclear dysfunction, offering a promising avenue for treating these currently intractable neurodegenerative diseases.
- 30 September 2023
- Published by Springer Nature
- p. 253-270
The Multifaceted Regulation of TDP-43 Condensates at the Intersection of Physiology and Pathology: Implications for Neurodegenerative Diseases
- 30 September 2023
- Published by Springer Nature
- p. 253-270
The Multifaceted Regulation of TDP-43 Condensates at the Intersection of Physiology and Pathology: Implications for Neurodegenerative Diseases
- 15 November 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (22)
Candesartan prevents arteriopathy progression in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy model
Cerebral small vessel disease (CSVD) causes dementia and gait disturbance due to arteriopathy. Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is a hereditary form of CSVD caused by loss of high-temperature requirement A1 (HTRA1) serine protease activity. In CARASIL, arteriopathy causes intimal thickening, smooth muscle cell (SMC) degeneration, elastic lamina splitting, and vasodilation. The molecular mechanisms were proposed to involve the accumulation of matrisome proteins as substrates or abnormalities in transforming growth factor β (TGF-β) signaling. Here, we show that HTRA1−/− mice exhibited features of CARASIL-associated arteriopathy: intimal thickening, abnormal elastic lamina, and vasodilation. In addition, the mice exhibited reduced distensibility of the cerebral arteries and blood flow in the cerebral cortex. In the thickened intima, matrisome proteins, including the hub protein fibronectin (FN) and latent TGF-β binding protein 4 (LTBP-4), which are substrates of HTRA1, accumulated. Candesartan treatment alleviated matrisome protein accumulation and normalized the vascular distensibility and cerebral blood flow. Furthermore, candesartan reduced the mRNA expression of Fn1, Ltbp-4, and Adamtsl2, which are involved in forming the extracellular matrix network. Our results indicate that these accumulated matrisome proteins may be potential therapeutic targets for arteriopathy in CARASIL.
- 15 November 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (22)
Candesartan prevents arteriopathy progression in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy model
Cerebral small vessel disease (CSVD) causes dementia and gait disturbance due to arteriopathy. Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is a hereditary form of CSVD caused by loss of high-temperature requirement A1 (HTRA1) serine protease activity. In CARASIL, arteriopathy causes intimal thickening, smooth muscle cell (SMC) degeneration, elastic lamina splitting, and vasodilation. The molecular mechanisms were proposed to involve the accumulation of matrisome proteins as substrates or abnormalities in transforming growth factor β (TGF-β) signaling. Here, we show that HTRA1−/− mice exhibited features of CARASIL-associated arteriopathy: intimal thickening, abnormal elastic lamina, and vasodilation. In addition, the mice exhibited reduced distensibility of the cerebral arteries and blood flow in the cerebral cortex. In the thickened intima, matrisome proteins, including the hub protein fibronectin (FN) and latent TGF-β binding protein 4 (LTBP-4), which are substrates of HTRA1, accumulated. Candesartan treatment alleviated matrisome protein accumulation and normalized the vascular distensibility and cerebral blood flow. Furthermore, candesartan reduced the mRNA expression of Fn1, Ltbp-4, and Adamtsl2, which are involved in forming the extracellular matrix network. Our results indicate that these accumulated matrisome proteins may be potential therapeutic targets for arteriopathy in CARASIL.
- Open Access
- 21 September 2021
- Published by Springer Nature in Communications Biology
- Vol. 4 (1) , 1-11
Age-related demethylation of the TDP-43 autoregulatory region in the human motor cortex
In amyotrophic lateral sclerosis (ALS), TAR DNA-binding protein 43 (TDP-43), which is encoded by TARDBP, forms aggregates in the motor cortex. This aggregate formation may be triggered by an increase in the TDP-43 level with aging. However, the amount of TDP-43 is autoregulated by alternative splicing of the TARDBP 3′UTR, and how this autoregulation is affected by aging remains to be elucidated. We found that DNA demethylation in the autoregulatory region in the TARDBP 3′UTR reduced alternative splicing and increased TARDBP mRNA expression. Furthermore, in the human motor cortex, we found that this region was demethylated with aging, resulting in increased expression of TARDBP mRNA. The acceleration of DNA demethylation in the motor cortex was associated with the age of ALS onset. In summary, the dysregulation of TDP-43 autoregulation by age-related DNA demethylation in the motor cortex may explain the contribution of aging and motor system selectivity in ALS.
- 21 September 2021
- Published by Springer Nature in Communications Biology
- Vol. 4 (1) , 1-11
Open AccessAge-related demethylation of the TDP-43 autoregulatory region in the human motor cortex
In amyotrophic lateral sclerosis (ALS), TAR DNA-binding protein 43 (TDP-43), which is encoded by TARDBP, forms aggregates in the motor cortex. This aggregate formation may be triggered by an increase in the TDP-43 level with aging. However, the amount of TDP-43 is autoregulated by alternative splicing of the TARDBP 3′UTR, and how this autoregulation is affected by aging remains to be elucidated. We found that DNA demethylation in the autoregulatory region in the TARDBP 3′UTR reduced alternative splicing and increased TARDBP mRNA expression. Furthermore, in the human motor cortex, we found that this region was demethylated with aging, resulting in increased expression of TARDBP mRNA. The acceleration of DNA demethylation in the motor cortex was associated with the age of ALS onset. In summary, the dysregulation of TDP-43 autoregulation by age-related DNA demethylation in the motor cortex may explain the contribution of aging and motor system selectivity in ALS.
- Open Access
Age-related demethylation of the TDP-43 autoregulatory region in the human motor cortex
In amyotrophic lateral sclerosis (ALS), TAR DNA-binding protein 43 (TDP-43), which is encoded by TARDBP , forms aggregates in the motor cortex. This aggregate formation may be triggered by an increase in the TDP-43 level with aging. However, the amount of TDP-43 is autoregulated by alternative splicing of the TARDBP 3’UTR, and how this autoregulation is affected by aging remains to be elucidated. We found that DNA demethylation in the autoregulatory region in the TARDBP 3′UTR reduced alternative splicing and increased TARDBP mRNA expression. Furthermore, in the human motor cortex, we found that this region was demethylated with aging, resulting in increased expression of TARDBP mRNA. The acceleration of DNA demethylation in the motor cortex was associated with the age of ALS onset. In summary, the dysregulation of TDP-43 autoregulation by age-related DNA demethylation in the motor cortex may explain the contribution of aging and motor system selectivity in ALS.
Open AccessAge-related demethylation of the TDP-43 autoregulatory region in the human motor cortex
In amyotrophic lateral sclerosis (ALS), TAR DNA-binding protein 43 (TDP-43), which is encoded by TARDBP , forms aggregates in the motor cortex. This aggregate formation may be triggered by an increase in the TDP-43 level with aging. However, the amount of TDP-43 is autoregulated by alternative splicing of the TARDBP 3’UTR, and how this autoregulation is affected by aging remains to be elucidated. We found that DNA demethylation in the autoregulatory region in the TARDBP 3′UTR reduced alternative splicing and increased TARDBP mRNA expression. Furthermore, in the human motor cortex, we found that this region was demethylated with aging, resulting in increased expression of TARDBP mRNA. The acceleration of DNA demethylation in the motor cortex was associated with the age of ALS onset. In summary, the dysregulation of TDP-43 autoregulation by age-related DNA demethylation in the motor cortex may explain the contribution of aging and motor system selectivity in ALS.
- 1 October 2019
- Published by Elsevier in Neurobiology of Disease
- Vol. 130, 104534
Non-genetically modified models exhibit TARDBP mRNA increase due to perturbed TDP-43 autoregulation
- 1 October 2019
- Published by Elsevier in Neurobiology of Disease
- Vol. 130, 104534
Non-genetically modified models exhibit TARDBP mRNA increase due to perturbed TDP-43 autoregulation